Skip to content

Improving Therapeutic Patient Education for Atopic Dermatitis: Evaluation of a Parent Handbook

Improving Therapeutic Patient Education for Atopic Dermatitis: Evaluation of a Parent Handbook

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03722706
Enrollment
246
Registered
2018-10-29
Start date
2019-02-26
Completion date
2020-03-30
Last updated
2020-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dermatitis, Atopic

Brief summary

The objective of this research is to evaluate the effectiveness of an educational handbook for parents of children with atopic dermatitis (AD) in improving clinical outcomes for pediatric patients with AD and their parents. The handbook was developed by an interdisciplinary team of healthcare providers to facilitate therapeutic patient education as a routine component of care for pediatric patients with atopic dermatitis (AD). Patient education is an important element of practice management guidelines for AD, particularly given complex treatment plans and high rates of non-adherence in this population. Parents of children with AD will be randomized into either the handbook arm (handbook provided as an adjunct to standard AD management with a healthcare provider at Boston Children's Hospital) or the control arm (standard management alone). Participants will complete study measures at two time points: baseline (prior to a clinic visit appointment for AD care at Boston Children's Hospital), and 3-month follow-up. Data will be analyzed for change on study outcome measures (AD symptoms, AD severity, quality of life) and satisfaction with the handbook.

Interventions

OTHEREducational handbook

The intervention being evaluated in this study is an educational handbook for parents of children with atopic dermatitis (AD). The handbook was developed and written by the interdisciplinary study team (psychologist, allergist, nurse practitioner, dermatologists, primary care physician, dietitian). Content was based on practice guidelines for AD management, consensus recommendations for therapeutic patient education for AD, and clinical experience of our study team. Content includes topics central to effective AD management, such as pathophysiology/course, elements of treatment plans, and strategies to improve quality of life, such as breaking the itch-scratch cycle, improving sleep, and coping with social-emotional issues.

Sponsors

Pfizer
CollaboratorINDUSTRY
Boston Children's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
30 Days to 16 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of atopic dermatitis * Scheduled for clinic visit for evaluation/management of atopic dermatitis at Boston Children's Hospital

Exclusion criteria

* Parent is Spanish speaking * Parent is foster parent

Design outcomes

Primary

MeasureTime frameDescription
Patient-Oriented Eczema Measure (POEM)baseline to 3-month follow-upparent-report of child's atopic dermatitis symptoms

Secondary

MeasureTime frameDescription
Eczema Area and Severity Index (EASI)baseline to 3-month follow-uphealthcare provider-rating of atopic dermatitis severity
Infant's Dermatitis Quality of Life Index (IDQOL)baseline to 3-month follow-upQuality of life associated with atopic dermatitis (for patients under 4 years)
Children's Dermatology Life Quality Index (CDLQI)baseline to 3-month follow-upQuality of life associated with atopic dermatitis (for patients 4-16 years)
Dermatology Family Impact Questionnaire (DFI)baseline to 3-month follow-upParent quality of life associated with atopic dermatitis

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026